Catalent(CTLT) - 2024 Q3 - Quarterly Results

• Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. (1) • Q3'24 Adjusted EBITDA of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. "I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth. We also continued our momentum in both the Biologics segment and the Pharma and Consumer Health segment, w ...